554 related articles for article (PubMed ID: 14529544)
1. Anticancer antifolates: current status and future directions.
McGuire JJ
Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544
[TBL] [Abstract][Full Text] [Related]
2. Deaza analogs of folic acid as antitumor agents.
Kisliuk RL
Curr Pharm Des; 2003; 9(31):2615-25. PubMed ID: 14529545
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I.
Gangjee A; Jain HD; Kurup S
Anticancer Agents Med Chem; 2007 Sep; 7(5):524-42. PubMed ID: 17896913
[TBL] [Abstract][Full Text] [Related]
5. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
6. Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance.
Takemura Y; Kobayashi H; Miyachi H
Int J Hematol; 1997 Dec; 66(4):459-77. PubMed ID: 9479873
[TBL] [Abstract][Full Text] [Related]
7. Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets.
Assaraf YG; Ifergan I; Kadry WN; Pinter RY
J Theor Biol; 2006 Jun; 240(4):637-47. PubMed ID: 16352313
[TBL] [Abstract][Full Text] [Related]
8. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
[TBL] [Abstract][Full Text] [Related]
10. Biological and biochemical properties of new anticancer folate antagonists.
Fry DW; Jackson RC
Cancer Metastasis Rev; 1987; 5(3):251-70. PubMed ID: 3549036
[TBL] [Abstract][Full Text] [Related]
11. Cancer research: from folate antagonism to molecular targets.
Bertino JR
Best Pract Res Clin Haematol; 2009 Dec; 22(4):577-82. PubMed ID: 19959110
[TBL] [Abstract][Full Text] [Related]
12. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
14. Classical and nonclassical furo[2,3-d]pyrimidines as novel antifolates: synthesis and biological activities.
Gangjee A; Devraj R; McGuire JJ; Kisliuk RL; Queener SF; Barrows LR
J Med Chem; 1994 Apr; 37(8):1169-76. PubMed ID: 8164259
[TBL] [Abstract][Full Text] [Related]
15. Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells.
Seither RL; Trent DF; Mikulecky DC; Rape TJ; Goldman ID
J Biol Chem; 1989 Oct; 264(29):17016-23. PubMed ID: 2529254
[TBL] [Abstract][Full Text] [Related]
16. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II.
Gangjee A; Jain HD; Kurup S
Anticancer Agents Med Chem; 2008 Feb; 8(2):205-31. PubMed ID: 18288923
[TBL] [Abstract][Full Text] [Related]
18. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)].
Nakamura T; Ueda T; Uchida M
Gan To Kagaku Ryoho; 1992 Mar; 19(3):409-20. PubMed ID: 1543370
[TBL] [Abstract][Full Text] [Related]
19. Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs.
McGuire JJ; Haile WH
Biochem Pharmacol; 2009 Apr; 77(7):1161-72. PubMed ID: 19174154
[TBL] [Abstract][Full Text] [Related]
20. Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.
Jackman AL; Boyle FT; Harrap KR
Invest New Drugs; 1996; 14(3):305-16. PubMed ID: 8958186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
